XCEEDANCE
3.3.2020 09:02:14 CET | Business Wire | Press release
Xceedance , a global provider of insurance consulting, managed services, technology, data sciences, and blockchain solutions, today launched its life insurance and reinsurance practice and announced the establishment of an office in Liechtenstein to serve life re/insurance markets.
The practice focuses on partnering with existing and start-up life re/insurance organisations and insurtech providers, offering services such as interim management, strategic consulting, product development, actuarial services, sales strategy consulting, Solvency II Pillar 1-2 support, and reinsurance optimisation. In addition, Xceedance can help carriers with legacy transformation to better manage new and existing business, and to transact run-off portfolios.
Markus Brugger and Mark Lucas will jointly direct the newest international office of Xceedance, as leaders of the life insurance and reinsurance sectors respectively.
“Liechtenstein is a significant financial services hub, including for worldwide life re/insurers, and our rapidly growing company is especially skilled in supporting the full range of insurance operations, as we help our global clients gain new business, grow revenues and minimise expenses,” said Arun Balakrishnan, CEO, Xceedance. “We are excited to locate an office in Liechtenstein and expand opportunities for direct interaction with diverse life re/insurance organisations, both in the EMEA region and worldwide.”
“Liechtenstein is a well-established global insurance marketplace, and Xceedance can help and support life re/insurers worldwide to strengthen their operations and enter new markets,” said Markus Brugger.
“We are excited to join a dynamic company such as Xceedance and look forward to building the company’s life re/insurance consulting and technology services to assist the industry in addressing pressing challenges and diverse market opportunities,” said Mark Lucas.
Mr. Brugger has 30 years of life re/insurance experience and was president of the Liechtenstein Insurance Association from 2012 to 2014. He has held senior roles with Winterthur Re, Cologne Re, and PartnerRe, and was CEO for 17 years at PrismaLife and Liechtenstein Life. Mr. Brugger joins Xceedance from Grant Thornton Liechtenstein/Switzerland, where he led the insurance advisory practice.
Mr. Lucas has 35 years of industry experience at Guy Carpenter in Denmark, U.S. Re in Switzerland, and most recently at JLT Re in Switzerland, where he was general manager. Mr. Lucas has developed several new reinsurance products over his career and brings a wealth of life reinsurance knowledge to Xceedance.
About Xceedance
Xceedance (www.xceedance.com ) is a global provider of strategic consulting, actuarial, and managed services, technology, and data sciences to property/casualty and life insurance organisations. Domiciled in Bermuda, with offices in the United States, United Kingdom, Germany, Liechtenstein, Poland, India, and Australia, Xceedance helps re/insurers launch new products, drive operations, implement intelligent technology and blockchain solutions, deploy advanced analytic capabilities, and achieve business process optimisation. The experienced insurance professionals at Xceedance enable re/insurers, brokers, TPAs, agents, and program administrators worldwide to enhance policyholder service, enter new markets, boost workflow productivity, and improve profitability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005108/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom